.
Hospital Clinical Pharmacy
Study Course Description
Course Description Statuss:Approved
Course Description Version:9.00
Study Course Accepted:04.01.2023 10:50:36
| Study Course Information | |||||||||
| Course Code: | FLK_043 | LQF level: | All Levels | ||||||
| Credit Points: | 2.00 | ECTS: | 3.00 | ||||||
| Branch of Science: | Clinical Medicine | Target Audience: | Clinical Pharmacy | ||||||
| Study Course Supervisor | |||||||||
| Course Supervisor: | Aleksandra Bule | ||||||||
| Study Course Implementer | |||||||||
| Structural Unit: | Department of Pharmacology | ||||||||
| The Head of Structural Unit: | |||||||||
| Contacts: | Riga, 13 Pilsonu Street, Santa[pnkts]Purvina rsu[pnkts]lv; Indra[pnkts]Dumbergarsu[pnkts]lv; +371 67613517 | ||||||||
| Study Course Planning | |||||||||
| Full-Time - Semester No.1 | |||||||||
| Lectures (count) | 5 | Lecture Length (academic hours) | 2 | Total Contact Hours of Lectures | 10 | ||||
| Classes (count) | 7 | Class Length (academic hours) | 2 | Total Contact Hours of Classes | 14 | ||||
| Total Contact Hours | 24 | ||||||||
| Study course description | |||||||||
| Preliminary Knowledge: | Clinical pharmacology and pharmacotherapy | ||||||||
| Objective: | 1. Become familiar with drug use in hospital, data presenting opportunities (DDD/1000 bed days). Give deeper understanding of topics about safe and rational drug use in hospital setting, drug dosing, also in special patient groups, for patients with organ failure, as well about therapeutic drug monitoring opportunities and main principles. 2. Improve student skills in pharmacotherapeutic problem identification (e.g. drug side effects and drug interactions), documentation and resolving. | ||||||||
| Topic Layout (Full-Time) | |||||||||
| No. | Topic | Type of Implementation | Number | Venue | |||||
| 1 | Clinical and hospital pharmacy in European countries. Drug committee. Drug circulation in hospitals. Analysis of drug use. | Lectures | 1.00 | E-Studies platform | |||||
| Classes | 1.00 | auditorium | |||||||
| 2 | Drug dosing in specific patient groups and pharmaceutical incompatabilities | Lectures | 1.00 | E-Studies platform | |||||
| Classes | 1.00 | auditorium | |||||||
| 3 | Pharmacotherapeutic problems | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | auditorium | |||||||
| 4 | Drug side effects and interactions | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | auditorium | |||||||
| 5 | Therapeutic Drug monitoring | Lectures | 1.00 | auditorium | |||||
| Classes | 1.00 | auditorium | |||||||
| 6 | Presenting of clinical case | Classes | 2.00 | auditorium | |||||
| Assessment | |||||||||
| Unaided Work: | Answer to the question and analysis of clinical cases. | ||||||||
| Assessment Criteria: | Independent analysis of clinical case with presentation. In clinical case presentation there must be identified at least one real or potential problem with suggested solution. Answer to clinical pharmacist question bout drug administration/ interaction etc. | ||||||||
| Final Examination (Full-Time): | Exam | ||||||||
| Final Examination (Part-Time): | |||||||||
| Learning Outcomes | |||||||||
| Knowledge: | Describe common pharmacotherapy problems and basic principles of drug dosage adjustment. | ||||||||
| Skills: | Analyze clinical cases and identify pharmacotherapy problems. | ||||||||
| Competencies: | Independently analyze clinical cases, interpret real and potential pharmacotherapy problems and present a possible plan for solving these problems. | ||||||||
| Bibliography | |||||||||
| No. | Reference | ||||||||
| Required Reading | |||||||||
| 1 | Clinical key | ||||||||
| 2 | Dynamed | ||||||||
| 3 | Drug induced diseases: Prevention, Detection and Management. 3rd ed. | ||||||||
| 4 | Wiffen, Phil. Oxford American Handbook of Clinical Pharmacy, 2009 (akceptējams izdevums) | ||||||||
| Additional Reading | |||||||||
| 1 | Katzung. Basic & Clinical Pharmacology. 15th ed., 2021 | ||||||||
| 2 | Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 14th ed., 2022 | ||||||||
| 3 | Evidence-based Pharmacy. Phil Wiffen (Eur J Hosp Pharm 2013). | ||||||||
| Other Information Sources | |||||||||
| 1 | Zāļu valsts aģentūra | ||||||||
| 2 | European Medical Agency | ||||||||
